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A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in
combination with 12-h timed (22:00–10:00) flat infusion of 5-fluorouracil (5-FU) in metastatic breast cancer patients. This schedule
seems to reduce the occurrence of stomatitis of the docetaxel and infusional 5-FU regimen.
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Biological circadian rhythms may affect the tolerability and
efficacy of 5-fluorouracil (5-FU). The chrono-modulated regimen
of 5-FU, with maximum delivery at 1600, reduces 5-FU toxicity and
increase 5-FU median dose intensity (Le ´vi, 1997). We associated
12-h timed (22:00–10:00) flat infusion (
22:00–10:00TFI) of 5-FU to
docetaxel (dTX) to exploit the increased activity of dehydropyr-
imidine dihydrogenase in human mononuclear cells and the
reduced cell replication activity of human bone marrow and of the
oral and rectal mucosa, during the night hours compared to
daytime (Caussanel et al, 1990; Smaaland et al, 1991).
22:00–10:00TFI
traces the 12h circadian-timed infusion of 5-FU (22:00–10:00 with
maximum delivery at 0400) and may contribute to increasing its
tolerability, making administration easier than the chrono-
modulated infusion. The objectives of the present dose-finding
study were to determine the maximum-tolerated dose (MTD) and
the recommended dose (RD) of this 5-FU/dTX schedule in
metastatic breast cancer patients.
PATIENTS AND METHODS
Patient eligibility criteria were: histologically or cytologically
documented breast cancer and proven metastatic or recurrent
breast cancer; measurable or evaluable metastatic disease; WBC
count X4 10
3mm
 3, neutrophils X2 10
3mm
 3, platelets
X100 10
3mm
 3, hemoglobin X10 gdl
 1, serum creatinine
p1.2mgdl
 1, total bilirubin p1.5 times the upper normal limit,
AST and ALT p1.5 times the upper normal limit; age between 18
and 75 years; World Health Organisation (WHO) performance
status p2. The study was approved by the Local Ethics Committee.
Prior chemotherapy for metastatic disease was not allowed. The
exclusion criteria included: peripheral neuropathy, uncontrolled
infection, diabetes and cardiac disease.
The treatment schedule consisted of a 1h i.v. dTX (Taxotere
s)
infusion on day 1 and a 12-h timed (22:00–10:00) flat i.v. 5-FU
(Fluorouracil TEVA
s)i n f u s i o n ,o v e r5d a y s ,e v e r y2 1d a y s .F o u r
escalation dose levels of dTX plus 5-FU were planned: 5-FU
700mgm
 2day
 1 associated to dTX 80 and 85mgm
 2 in the first
two dose levels, respectively; then, 5-FU dose levels were increased to
800 and 900mgm
 2day
 1 in the other two steps. Implantation of a
venous access device was required for 5-FU administration via a
programmed portable pump (Cadd-Plus, Sevit) that administered 5-
FU at a given constant rate for a period of 12h. Treatment was
routinely administered on an outpatient basis. The planned dose-
escalation strategy combined the intra- and interpatient approach
(Simon et al, 1997). The MTD was defined as the dose at which at least
50% of patients developed dose-limiting toxicity (DLT). In case of
DLT, as defined in the treatment plan, treatment was continued at the
dose level immediately below. This dose was the RD for phase II trials.
Granulocyte colony-stimulating factor (G-CSF) was administered at
the first occurrence of grade (G)4 neutropenia due to its high expected
rate, in order to prevent febrile neutropenia and treatment delays; in
the subsequent cycles, prophylactic G-CSF treatment was adminis-
tered for 5 days, after the occurrence of G4 neutropenia. Complete
blood cell count was performed on days 1, 6, 8, 12, every cycle.
Dose-limiting toxicity included: febrile neutropenia requiring
i.v. antibiotics or G4 neutropenia resistant to G-CSF administra-
tion (failure to recover neutrophils X1.5 10
3mm
 3 on day 21 of
each cycle); grade 4 thrombocytopenia; hemoglobin o6.5gdl
 1;
grade 3–4 nonhaematological toxicity (excluding alopecia and
nausea). Toxicity was graded according to the National Cancer
Institute Common Toxicity Criteria (NCI-CTC). Before entering
the study, each patient underwent medical history, physical
examination, complete blood cell count, serum biochemistry,
computed tomography of the chest and abdomen, bone scan, an
electrocardiogram and other investigations as clinically indicated.
Tumour imaging was repeated every three treatment cycles. Received 4 February 2004; revised 7 May 2004; accepted 10 May 2004;
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criteria. Time to disease progression and survival were assessed
using the methods of Kaplan and Meier.
RESULTS
Fourteen patients were enrolled. A summary of baseline patient
characteristics is illustrated in Table 1. A total of 88 cycles were
administered, with a median of six cycles per patient (1–12); the
median number of dose-escalations per patient was 2 (1–4).
The fourth dose level (dTX 85mgm
 2 and 5-FU
900mgm
 2day
 1) represented the MTD (Table 2): ten patients
were treated and 27 cycles were administered. Dose-limiting
toxicities were observed in five of 10 patients (50%): two patients
experienced grade (G)4 diarrhoea; two patients, G3 diarrhoea; one
patient, G3 mucositis (10%) and febrile G3 neutropenia. Each of
the five patients received subsequent cycles at the third dose level
without showing DLTs.
The third dose level (dTX 85mgm
 2 and 5-FU
800mgm
 2day
 1) represented the RD: 12 patients were treated
and 34 cycles were administered. Dose-limiting toxicities were not
observed and chemotherapy was well tolerated (Table 3): Grade 1–
2 diarrhoea in 42% of patients and 21% of cycles; G1–2 stomatitis
in 33% of patients and 53% of cycles; G 1–2 nausea/vomiting was
observed in 50% of patients and 32% of cycles. Grade 2 alopecia
was present in all patients. No toxic death was observed. One case
of thrombosis related to the venous access device was observed.
At the RD, G4 neutropenia was observed in 50% of patients (six
of 12) and in 47% of cycles (16 of 34); G3–4 neutropenia 79% (27
of 34). Overall, it has been observed in 36% (32 of 88) of cycles.
Patients showing G4 neutropenia were all treated with G-CSF. The
median time to neutrophil nadir was on day 8 and the median
duration of G-CSF administration was 5 days. One patient
experienced febrile G3 neutropenia at MTD.
The median dose intensity administered was 1333mgm
 2
week
 1 (900–1500) and 28.3mgm
 2week
 1 (17–28.3) for
5-FU and dTX, respectively. Patients received an average dose
intensity of 1321mgm
 2week
 1 (a: 0.05, CI: 749) for 5-FU and
of 27.7mgm
 2week
 1 (a: 0.05, CI: 70.3) for dTX.
In all, 13 patients were assessable for treatment efficacy. Two
complete and six partial responses were observed giving an overall
response rate of 61% (a: 0.05, CI: 728). The median time to
progression was 10 months (4–28 months) and the median overall
survival was 25 months (4 to 46þ months).
DISCUSSION
The RD for phase II studies of this dTX/5-FU schedule (dTX
85mgm
 2, day 1; 5-FU 800mgm
 2day
 1 in
22:00–10:00TFI) shows a
projected dose intensity equivalent to that proposed by Lortholary
et al (2000) (dTX 85mgm
 2 day 1; 5-FU 750mgm
 2day
 1 5-day
continuous infusion, every 3 weeks) (). These RDs were well
tolerated with the use of G-CSF. No DLTs were observed in the 12
treated patients and 34 administered cycles. Nonhaematological
toxicity was characterised by G1–2 diarrhoea and stomatitis. The
earlier dose-finding studies of docetaxel in combination with 5-FU
in advanced breast cancer show that mucositis (stomatitis and
diarrhoea) and neutropenia represented the DLTs at the MTD
(Ando et al, 1998; Petit et al, 1999). In our study and in that by
Lortholary et al, neutropenia was common but recovered after
medical G-CSF management.
In the study by Lortholary et al, few instances of febrile
neutropenia were observed and stomatitis represented the DLT at
the MTD; at the RD, 40% (two of five) of patients experienced G3
dose-limiting stomatitis and G4 neutropenia was reported in four of
five patients (Lortholary et al, 2000). The recently published phase II
study by Lortholary confirms that: neutropenia is the most common
toxic event (G3–4, 54% of patients; febrile neutropenia, 24% of
patients); stomatitis G3–4 is a frequent event (26% of patients,
approximately 6% of cycles); G3 diarrhoea occurs in 7% of patients
(1% cycles) (Lortholary et al, 2003). Even if in the present study the
use of G-SCF did not allow to report the duration of neutropenia, no
instance of febrile neutropenia was observed at the RD.
In the present study, at the RD, nonhaematological toxicity was
characterised by G1–2 diarrhoea (42% of patients and 21% of the
cycles) and G1–2 stomatitis (33% of the patients and 53% of the
cycles). The present data suggest that the
22:00–10:00TFI of 5-FU
may increase the nonhaematological tolerability of the 5-FU/dTX
Table 1 Patient characteristics
No. (%)
Number of patients 14 (100)
Median age (years) 52
Range 36–69
WHO
a performance status
0 11 (78)
X1 3 (22)
Adjuvant therapy
Chemotherapy with anthracyclines 10 (71)
Chemotherapy without anthracyclines 3 (21)
Hormonal therapy 10 (71)
Previous metastatic breast cancer therapy
Hormonal therapy 1 (7)
Disease sites
Soft tissue and skin 2 (14)
Liver 6 (43)
Lung and pleura 7 (50)
Bone 4 (29)
Brain 1 (7)
Number of organs involved
1 6 (43)
2 8 (57)
aWHO¼World Health Organisation.
Table 2 DLTs according to the dose-escalation scheme
Dose levels
Docetaxel (mgm
 2)–5-
FU (mgm 
2day
 1) No. of patients
a No. of cycles
No. of patients with
DLT/total patients (%)
No. of cycles with DLT/
total cycles (%) DLTs
I 80–700 5 15 — — —
II 85–700 8 12 — — —
III 85–800 12 34 — — —
IV 85–900 10 27 5/10 (50) 5/27 (18) Two G3 diarrhoea
Two G4 diarrhoea
One G3 mucositis and
febrile neutropenia
aIntra- and interpatient dose escalation.DLT¼dose-limiting toxicity; 5-FU¼5-fluorouracil.
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stomatitis.
Among the oral fluoropirimidine formulations, capecitabine
mimicks protracted infusion of 5-FU. The present data are
particularly significant to this concern in view of a potential
comparison between the most tolerable and effective sche-
dules of dTX and 5-FU or capecitabine in metastatic breast
cancer.
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Table 3 Nonhaematological toxicity at recommended dose and MTD
Cycles Patients
a
Dose levels
III IV III IV
Docetaxel (mgm
 2)-5-fluorouracile (mgm
 2day
 1)
85–800 85–900 85–800 85–900
Number
34 27 12 10
Grade (1–2) (3–4) (1–2) (3–4) (1–2) (3–4) (1–2) (3–4)
Nausea 10 — 6 — 5 — 3 —
(%) (29) (22) (42) (30)
Vomiting 1 — 5 2 1 — 1 1
(%) (3) (18) (7) (8) (10) (10)
Diarrhoea 7 — 6 4 5 — 2 4
(%) (21) (22) (15) (42) (20) (40)
Stomatitis 18 — 10 1 4 — 5 1
(%) (53) (37) (4) (33) (50) (10)
Neurosensory 3 — 11 — 1 — 1 —
(%) (9) (41) (8) (10)
Dermatitis — — 6 — — — 2 —
(%) (22) (20)
Asthenia 8 — 16 — 4 — 6 —
(%) (23) (59) (33) (60)
Fluid retention 6 — 15 — 3 — 3 —
(%) (18) (55) (25) (30)
Nail toxicity 4 — 10 — 2 — 2 —
(%) (12) (37) ( 17) (20)
aIntra- and interpatient dose escalation.MTD¼maximum-tolerated dose.
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